RNAC Q3 2021 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+425.8% YoY

Gross Profit

$24M100.0% margin

Operating Income

-$2M-8.1% margin

Net Income

-$18M-73.3% margin

EPS (Diluted)

$-4.66

QoQ Revenue Growth

+24.2%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$167M

Total Liabilities

$186M

Stockholders' Equity

-$19M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$5M	+425.8%
Gross Profit	$24M	$5M	+425.8%
Operating Income	-$2M	-$14M	+85.7%
Net Income	-$18M	-$10M	-83.9%